Table 1.
Demographic and clinical characteristics of the study population.
| Severe GHD (n = 38) | Mild GHD (n = 16) | Controls (n = 20) | p-value | |
| Age | 44.9 ± 14.0 | 48.2 ± 10.6 | 45.5 ± 12.0 | NS |
| Gender (M/F) | 23/15 | 3/11 | 9/11 | NS |
| NYHA class | 1.3 ± 0.5 | 1.1 ± 0.1 | 1.2 ± 0.1 | NS |
| Body mass index | 29.7 ± 6.8 | 31.4 ± 4.8 | 28.6 ± 4.4 | NS |
| SBP (mmHg) | 134.1 ± 16.1 | 133.6 ± 17.6 | 128.1 ± 10.3 | NS |
| DBP (mmHg) | 79.5 ± 10.8 | 81.8 ± 9.8 | 78.5 ± 11.1 | NS |
| SBP > 135 and/or DBP > 85 mmHg | 11 (28.4) | 6 (37.5) | 5 (25%) | NS |
| GH-peak (ng/mL) | 0.97 ± 0.84 | 8.31 ± 3.31 | NA | <0.0001 |
| IGF-1 (ng/mL) | 94.3 ± 64.6 | 130.5 ± 65.8 | NA | <0.05 |
| FT3 (mmol/L) | 4.2 ± 1.2 | 4.9 ± 1.6 | 5.3 ± 0.9 | NS |
| FT4 (mmol/L) | 12.9 ± 4.0 | 15.5 ± 3.8 | 14.2 ± 2.9 | NS |
Values are mean ± SD.
Legends: DBP, Diastolic Blood Pressure; GH, Growth Hormone; IGF-1, Insulin-Like Growth Factor; NA, Not Applicable; NYHA, New York Heart Association Functional Class; SBP, Systolic Blood Pressure; FT3, Free Triiodothyronine; FT4, Free Thyroxine.